Clinical Trial Update: Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating cabozantinib S-malate in younger patients with recurrent or refractory solid tumors; status completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Neoplasm
• Melanoma

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2023-12-21